Amoéba Reports a Net Loss of 8.3 Million Euros in 2025, Industrial Investments on the Rise
Greentech company Amoéba has released its 2025 annual results, showing an increasing operational deficit of 6.8 million euros compared to 5.7 million the previous year. These substantial investments reflect the preparation for the commercialization of its microbiological solutions expected in 2026.
Operational Performance and Financial Developments
The French biotech company concluded its 2025 fiscal year in an intensive phase of regulatory and pre-commercial development. The current operating result deteriorated to minus 6,784 thousand euros, compared to minus 5,663 thousand euros in 2024, a negative change of 1,121 thousand euros. This increase in deficit primarily stems from a rise in industrial deployment costs of 1,082 thousand euros, linked to the expansion of production capacities at the Chassieu site. Marketing and sales expenses also increased by 216 thousand euros, in preparation for the commercial launch of the biocontrol solution AXPERA scheduled for 2026. Conversely, research and development expenses decreased by 71 thousand euros, while general and administrative expenses dropped by 21 thousand euros, reflecting the gradual completion of the initial development cycle. Revenue remains nil. Subsidies received amounted to 695 thousand euros, up 93 thousand euros from 2024.
Financial Position and Net Results
The cash position significantly improved, reaching 4,722 thousand euros as of December 31, 2025, compared to 459 thousand euros a year earlier. This improvement stems from a capital increase carried out in July 2025 for 8,026 thousand euros and the drawing of 3,976 thousand euros under the non-convertible bond loan. The net result for the fiscal year amounted to minus 8,303 thousand euros, compared to minus 6,592 thousand euros in 2024, reflecting a negative financial result of 1,519 thousand euros related to the use of debt. Total financial debt stands at 12,238 thousand euros, primarily composed of a simple bond loan from Nice & Green for 11,400 thousand euros. Shareholders' equity remains negative at minus 5,361 thousand euros, compared to minus 10,410 thousand euros in 2024. Nice & Green, a reference shareholder, has confirmed its financial support at least until December 31, 2026, allowing Amoéba to ensure its operational continuity until that date.
Regulatory and Commercial Milestones
The year 2025 was marked by several regulatory and commercial milestones. ANSES initiated the conclusive phase of the evaluation for the market authorization of AXPERA. A distribution agreement was signed with Koppert for vineyards and vegetable crops in 18 European countries and the United States. A memorandum of understanding was also concluded with Syngenta concerning cereals and field crops in Europe and the United Kingdom. The AXPERA solution won the gold medal at the Bernard Blum award during the Annual Biocontrol Industry Meeting and the gold medal at the SIVAL Innovation 2026 competition. In the cosmetics sector, an agreement was signed in July 2025 with Oriental Beauty Valley in China.
